• PEAK Matrix®
    July 16, 2025

    In recent years, life sciences enterprises have reprioritized and overhauled their R&D investments. They now focus on streamlining their pipelines and shifting toward new and large molecules. This transformation has compelled aggressive cost containment initiatives, prompting…
  • PEAK Matrix®
    Aug. 26, 2026

    Order-to-Cash (O2C) is moving higher on the CFO agenda as enterprises seek to improve cash predictability, support evolving monetization models, and meet rising expectations for seamless stakeholder experiences. These priorities are accelerating demand for O2C products…
  • Provider Compendium
    Sep. 30, 2025

    In recent years, life sciences enterprises have reoriented their R&D investments, prioritizing pipeline efficiency and a strategic focus on large and novel molecules. This shift has intensified efforts around cost containment and created a stronger need…